|
|
|
|
|
|
最高研发阶段临床1期 |
首次获批国家/地区- |
首次获批日期- |
A Phase 1 Open-Label, Multiple Dose, Two Part Dose Escalation Study of ECP-1014 as a Treatment for Patients With Solid Tumor Cancers
The primary objective of this study is to evaluate the safety, tolerability, pharmacokinetics, and optimal recommended Phase 2 dose (RP2D) during a 28-day dosing period of ECP-1014 in patients with solid tumors and by evaluation of dose limiting toxicities.
100 项与 Euclises Pharmaceuticals, Inc. 相关的临床结果
0 项与 Euclises Pharmaceuticals, Inc. 相关的专利(医药)
100 项与 Euclises Pharmaceuticals, Inc. 相关的药物交易
100 项与 Euclises Pharmaceuticals, Inc. 相关的转化医学